Any kind of malignancies
Conditions
Interventions
We use two doses of influenza vaccine to prevent influenza infection and measure HI titer.
Sponsors
Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1>Patients of more than 20 years old with the diagnosis of malignancy from pathology receiving chemo therapy. We choose chemotherapy as suspecting decrease of lymphocyte, using prednisolone more than 20mg for treatment or reducing side effect of chemotherapy, or molecular target therapy reducing the immune system. 2>Patients reseived immunoglobulins within the presious 6 weeks prior to vaccination. 3>Patients with a life expectancy of at least 6months. 4>The patients whose ECOG performance status are 0 to 2. 5>The patients who are more than 20 years old, and agree to participate in this study with document.
Exclusion criteria
Exclusion criteria: 1>The patients who had fever at the time of vaccination. 2>The patients who had an acute febrile illness at the time of vaccination. 3>The patients known anaphylactic shock to the ingredient of the influenza vaccine. 4>The patients received corticosteroid (0.3mg/kg of prednisone minimum dose.) 5>The patients with platelet count less than 20000/µl. 6>The patients received a live vaccine within 4weeks or inactivating vaccine or toxoid within 1week. 7>The patients treating only with hormonal therapy. 8>The patients whose doctor judge as ineligible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We evaluate the efficacy of two doses of influenza vaccine in patients with malignancies receiving chemotherapy. Influenza immunity was defined as HI titre of >40 to all three influenza subtypes after vaccination. | — |
Countries
Japan
Contacts
Public ContactYukinari Sanada
Department of Medicine, Kobe University Graduate School of Medicine Division of Medical Oncology/Hematology
Outcome results
None listed